A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Ivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary) ; VX 121 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 30 May 2019 Status changed from active, no longer recruiting to completed.
- 05 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
- 05 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 May 2019.